Globus Medical Reports Strong Q4 & FY25 Results, Raises 2026 EPS Guidance
Summary
Globus Medical Inc. announced robust fourth quarter and full-year 2025 financial results, exceeding expectations with significant sales and earnings growth, and raised its non-GAAP diluted EPS guidance for full-year 2026.
Key Events
-
Strong Q4 and Full-Year 2025 Results
Worldwide net sales for Q4 2025 increased 25.7% to $826.4 million, and full-year 2025 sales rose 16.7% to $2.94 billion.
-
Exceptional Earnings Growth
GAAP diluted EPS for Q4 2025 surged 442.6% to $1.03, and non-GAAP diluted EPS increased 52.1% to $1.28. Full-year GAAP EPS grew 425.4% to $3.92, with non-GAAP EPS up 30.8% to $3.98.
-
2026 EPS Guidance Raised
The company updated its non-GAAP fully diluted EPS guidance for full-year 2026 to a range of $4.40 to $4.50, an increase from the previous range of $4.30 to $4.40, while reaffirming revenue guidance.
-
Nevro Acquisition Contribution
The Nevro acquisition significantly contributed to sales, adding $99.7 million in Q4 2025 and $293.6 million for the full year, enhancing overall growth.
Analysis
This 8-K filing signals strong operational momentum for Globus Medical, highlighted by robust double-digit sales and earnings growth for both the fourth quarter and full-year 2025. The significant increase in GAAP and non-GAAP EPS demonstrates effective cost management and successful integration of the Nevro acquisition. The decision to raise the non-GAAP EPS guidance for 2026, while reaffirming revenue, indicates management's confidence in continued profitability and operational efficiency. This positive financial update, following preliminary sales figures reported in January, is likely to be viewed favorably by investors, potentially boosting investor sentiment and supporting the company's valuation as it focuses on scaling growth and expanding its product pipeline.
At the time of this filing, GMED was trading at $93.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $51.79 to $101.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.